LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Roller Warriors skate over 1970s-era stereotypes with message of empowerment
Kansas City Roller Warriors are in the business of self-expression, strengthening team bonds and legitimizing their sport, skaters say. The player-owned roller derby league operates as a limited liability company, but essentially functions as a non-profit, organizers said. Having grown from grassroots origins in 2004 to now a member of the Women’s Flat Track Derby…
Prairie Village company’s Firefly lends serenity, tech to backyard fireworks
Prairie Village-based Winco Fireworks is officially launching Firefly, a remote firework firing system, introducing a tech blend to the formerly traditional firework industry and backyard Fourth of July celebrations. “It’s a really neat invention,” said Michael Collar, president of Winco Fireworks, which focuses on consumer fireworks. “There’s a lot of commercial firework companies that do…
We Create KC report: Startup investment soared to $540M in 2017
A startling statistic for those who think capital merely flies over the Midwest: Kansas City saw a 69 percent increase in startup investment from 2016 to 2017, according to KCSourceLink’s We Create KC report. All told, early-stage businesses classified by KCSourceLink as startups — typically defined as those with 20 or fewer employees — nabbed…
Hack Midwest offers coders freedom through 24-hour app creation competition
Technologists are often surprised by what they’re able to accomplish when they work together in a competitive format, Mike Gelphman said. That’s part of the reason Hack Midwest is returning this summer with the objective to inspire more techies to embrace their imagination, said Gelphman, founder of the competition, as well as KCITP, an area…